TD Cowen Maintains Sanofi(SNY.US) With Hold Rating, Maintains Target Price $67

Moomoo News01:32 ET · Ratings

Cautious Hold Rating on Sanofi Due to Safety Concerns and Limited Growth Prospects for Qfitlia

TipRanks18:15 ET · Ratings

Sanofi Consumer Healthcare India Limited Announces Postal Ballot Results

TipRanksMar 30 02:44 ET

Top FDA Vaccine Official Resigns Citing RFK Jr.'s 'Misinformation and Lies'

Seeking AlphaMar 29 07:46 ET

Sanofi Says With Qfitlia Approval, FDA Also Cleared Siemens Healthineers' Innovance Antithrombin Assay As Companion Diagnostic For Qfitlia

BenzingaMar 28 16:41 ET

Sanofi Hemophilia Treatment Receives FDA Approval

MT NewswiresMar 28 15:54 ET

FDA Approves Novel Treatment for Hemophilia A or B, With or Without Factor Inhibitors

PR NewswireMar 28 14:23 ET

European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading

MT NewswiresMar 28 11:09 ET

Japan Approves Sanofi's Dupixent as Treatment for Chronic Obstructive Pulmonary Disease

MT NewswiresMar 28 02:35 ET

Sanofi's Dupixent Gets Japanese Approval for Chronic Obstructive Pulmonary Disease

MT NewswiresMar 28 02:10 ET

RFK Jr. Reportedly Plans 10,000 Job Cuts in HHS With FDA, CDC, Medicare Affected

Seeking AlphaMar 27 08:22 ET

Sanofi's Chief Digital Officer Says Remote Work Means Employees Lose the 'Serendipity' Needed to Innovate

Yahoo FinanceMar 27 02:00 ET

Top Gap Ups and Downs on Wednesday: SAP, ASML, SONY and More

Moomoo NewsMar 26 18:00 ET · Markets

FDA Fast Tracks Sanofi's MRNA Vaccine for Chlamydia

Yahoo FinanceMar 26 08:15 ET

Marty Makary and Jay Bhattacharya Clear Senate Hurdles to Lead FDA and NIH

Seeking AlphaMar 26 06:56 ET

Sanofi Hits 4-week Low

Trading EconomicsMar 26 04:00 ET

Sanofi Gets US FDA Fast Track Designation for Chlamydia Vaccine Candidate

MT NewswiresMar 26 02:10 ET

Press Release: Chlamydia Vaccine Candidate Granted Fast Track Designation by the US FDA

SanofiMar 26 00:00 ET

J.P. Morgan Sticks to Its Hold Rating for Sanofi (SNYNF)

TipRanksMar 25 04:05 ET · Ratings

Sanofi's Tolebrutinib Granted FDA Priority Review For Non-Relapsing Secondary Progressive MS, Targeting Smoldering Neuroinflammation

BenzingaMar 25 02:24 ET